Whole genome sequencing in oncology: using scenario drafting to explore future developments

被引:14
作者
van de Ven, Michiel [1 ]
Simons, Martijn J. H. G. [2 ,3 ]
Koffijberg, Hendrik [1 ]
Joore, Manuela A. [2 ,3 ]
IJzerman, Maarten J. [1 ,4 ,5 ]
Retel, Valesca P. [1 ,6 ]
van Harten, Wim H. [1 ,6 ,7 ]
机构
[1] Univ Twente, Techn Med Ctr, Enschede, Netherlands
[2] Maastricht Univ, Med Ctr, Maastricht, Netherlands
[3] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
[4] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Netherlands Canc Inst Leeuwenhoek Hosp NKIAVL, Amsterdam, Netherlands
[7] Rijnstate Gen Hosp, Arnhem, Netherlands
关键词
Whole genome sequencing; Implementation; Scenario drafting; Uncertainty; Oncology; EVOLUTION; CARE;
D O I
10.1186/s12885-021-08214-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments facilitating or impeding the use of WGS as a molecular diagnostic in oncology through scenario drafting. Methods A four-step process was adopted for scenario drafting. First, the literature was searched for barriers and facilitators related to the implementation of WGS. Second, they were prioritized by international experts, and third, combined into coherent scenarios. Fourth, the scenarios were implemented in an online survey and their likelihood of taking place within 5 years was elicited from another group of experts. Based on the minimum, maximum, and most likely (mode) parameters, individual Program Evaluation and Review Technique (PERT) probability density functions were determined. Subsequently, individual opinions were aggregated by performing unweighted linear pooling, from which summary statistics were extracted and reported. Results Sixty-two unique barriers and facilitators were extracted from 70 articles. Price, clinical utility, and turnaround time of WGS were ranked as the most important aspects. Nine scenarios were developed and scored on likelihood by 18 experts. The scenario about introducing WGS as a clinical diagnostic with a lower price, shorter turnaround time, and improved degree of actionability, scored the highest likelihood (median: 68.3%). Scenarios with low likelihoods and strong consensus were about better treatment responses to more actionable targets (26.1%), and the effect of centralizing WGS (24.1%). Conclusions Based on current expert opinions, the implementation of WGS as a clinical diagnostic in oncology is heavily dependent on the price, clinical utility (both in terms of identifying actionable targets as in adding sufficient value in subsequent treatment), and turnaround time. These aspects and the optimal way of service provision are the main drivers for the implementation of WGS and should be focused on in further research. More knowledge regarding these factors is needed to inform strategic decision making regarding the implementation of WGS, which warrants support from all relevant stakeholders.
引用
收藏
页数:12
相关论文
共 30 条
[1]  
[Anonymous], 2020, TECHNOLOGY ASSESSMEN
[2]   The current state of scenario development: an overview of techniques [J].
Bishop, Peter ;
Hines, Andy ;
Collins, Terry .
FORESIGHT, 2007, 9 (01) :5-+
[3]   The origins and evolution of scenario techniques in long range business planning [J].
Bradfield, R ;
Wright, G ;
Burt, G ;
Cairns, G ;
Van Der Heijden, K .
FUTURES, 2005, 37 (08) :795-812
[4]   TRANSLATING GENOMICS FOR CLINICAL BENEFIT [J].
Caulfield, Mark .
POSTGRADUATE MEDICAL JOURNAL, 2019, 95 (1130) :686-686
[5]  
Central Committee on Research Involving Human Subjects, 2020, YOUR RES IS IT SUBJ
[6]   Three decades of scenario planning in Shell [J].
Cornelius, P ;
Van De Putte, A ;
Romani, M .
CALIFORNIA MANAGEMENT REVIEW, 2005, 48 (01) :92-+
[7]  
Gong Jun, 2018, Oncotarget, V9, P15792, DOI 10.18632/oncotarget.24353
[8]   Beyond Adoption: A New Framework for Theorizing and Evaluating Nonadoption, Abandonment, and Challenges to the Scale-Up, Spread, and Sustainability of Health and Care Technologies [J].
Greenhalgh, Trisha ;
Wherton, Joseph ;
Papoutsi, Chrysanthi ;
Lynch, Jennifer ;
Hughes, Gemma ;
A'Court, Christine ;
Hinder, Susan ;
Fahy, Nick ;
Procter, Rob ;
Shaw, Sara .
JOURNAL OF MEDICAL INTERNET RESEARCH, 2017, 19 (11)
[9]   Factors influencing organizational adoption and implementation of clinical genetic services [J].
Hamilton, Alison B. ;
Oishi, Sabine ;
Yano, Elizabeth M. ;
Gammage, Cynthia E. ;
Marshall, Nell J. ;
Scheuner, Maren T. .
GENETICS IN MEDICINE, 2014, 16 (03) :238-245
[10]   The triangular distribution as a proxy for the beta distribution in risk analysis [J].
Johnson, D .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES D-THE STATISTICIAN, 1997, 46 (03) :387-398